On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate cancer. Just six days later, James ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Novartis (NVS) to CHF 115 from CHF 110 and keeps a Buy rating on the ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF115.00. The company’s shares opened ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NOVN – Research Report), with a price ...

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

Eddie Howe's Carabao Cup winning Mags return to action today with a clash against Brentford at St. James' Park. It's been ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Florida Cancer Specialists & Research Institute, LLC (FCS) continues to expand the availability of life-changing and ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...